# Use of CTEP portfolio compounds to counteract phenotype conversion in GBM

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $54,237

## Abstract

Summary/Abstract
Despite a tremendous effort in basic science, clinical trials, drug development, and technical
advances in surgery and radiation oncology, glioblastoma remains incurable and improvements
in overall survival have been marginal. While radiotherapy is still one of the most effective
treatment options for glioblastoma, it cannot control the disease over time. This suggests that
novel combination therapies are desperately needed to improve radiation treatment outcome for
patients suffering from this disease. The studies outlined in this proposal are based on a
hypothesis that is backed by our extensive preliminary data and rigorous published data in the
literature. The overall hypothesis is that biomarker-based drug selection predicts synergistic
lethality of combination therapies in GICs and glioblastoma bulk tumor cell populations, prevents
radiation-induced GBM phenotype conversion and allows for individualized optimization of
radiotherapy. The three aims of the parent grant address this aspect of glioma biology using an
innovative tool to track GICs and their progeny, while leveraging the unique resources and
expertise available at UCLA and the NIH/NCI CTEP portfolio of drugs. This administrative
supplement to the parent grant will increase the diversity of our team and will add single cell
next generation sequencing to the aims.

## Key facts

- **NIH application ID:** 10598714
- **Project number:** 3R01CA260886-01A1S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Frank Pajonk
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $54,237
- **Award type:** 3
- **Project period:** 2022-01-01 → 2026-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10598714

## Citation

> US National Institutes of Health, RePORTER application 10598714, Use of CTEP portfolio compounds to counteract phenotype conversion in GBM (3R01CA260886-01A1S1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10598714. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*